Bio-Thera Solutions’ BAT8006 Shows Positive Phase I Results in Solid Tumor Treatment
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced positive Phase I clinical data for BAT8006...
Cancer
Medtronic Partners with APMG to Advance Orthopedic Treatment Services in China
US-based Medtronic Inc., (NYSE: MDT) has entered into a partnership with China’s private healthcare group...
NMPA Greenlights Oricell Therapeutics’ OriCAR-017 for Clinical Trials in Multiple Myeloma
The National Medical Products Administration (NMPA) has indicated on its website that Oricell Therapeutics Co.,...
Antengene Corp. Secures Licensing Deal with Hansoh Pharmaceutical for Xpovio in China
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced a significant licensing agreement with...
Burning Rock Partners with AstraZeneca to Develop Companion Diagnostics for Cancer Therapies
Guangzhou-based medical device giant Burning Rock (NASDAQ: BNR) has announced a strategic partnership with AstraZeneca...
BioCity Biopharma Receives FDA IND Approval for CD3-EGFR BsAb BC3448
China-based biotechnology company BioCity Biopharma has announced that it has received Investigational New Drug (IND)...
Ascentage Pharma’s Lisaftoclax (APG-2575) Gets FDA Green Light for Phase III Study
China-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the US...
Hansoh Pharmaceutical Regains Rights to Ameile After EQRx Partnership Cancellation
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced the cancellation of its partnership and...
Chia Tai Tianqing Secures Exclusive Rights to InventisBio’s D-1553 in China Licensing Deal
China-based Chia Tai Tianqing has signed a licensing agreement with compatriot firm InventisBio, securing exclusive...
Our United Corporation’s Linear Accelerator Approved as Innovative Medical Device by NMPA
Xi’an-based Our United Corporation has announced that its medical electronic linear accelerator has been approved...
BeiGene and Bristol-Myers Squibb/Celgene Settle Partnership, Termination Set for 2023
BeiGene (NASDAQ: BGNE) has announced a settlement and termination agreement with US firm Bristol-Myers Squibb/Celgene...
ABM Therapeutics’ ABM-1310 Earns Orphan Drug Designation for BRAF V600 Mutant Glioblastoma
Shanghai-based ABM Therapeutics Inc. has announced that it has received Orphan Drug Designation (ODD) from...
CASI Pharmaceuticals Enters Assignment Agreement with Mundipharma for Folotyn Commercialization in China
US-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has announced the execution of an assignment agreement with...
Astellas Pharma’s Zolbetuximab BLA Accepted by China’s CDE for Gastric Cancer Treatment
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...
GSK’s Jemperli Receives FDA Approval for First-Line Treatment of Advanced Endometrial Cancer
GSK plc (NYSE: GSK), a major UK pharmaceutical company, has announced that the US Food...
RemeGen’s Novel Bispecific Antibody RC148 Receives Clinical Trial Approval
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical trial...
Jiangsu Hengrui’s Camrelizumab and Apatinib Combo Accepted for FDA Review for HCC Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the US Food and Drug...
Jacobio Pharma’s Glecirasib Enters Breakthrough Therapy Review for Pancreatic Cancer Treatment
China-based Jacobio Pharma (HKG: 1167) has announced that its novel KRAS G12C inhibitor, glecirasib, has...
Lucence and Innovent Biologics Partner to Enhance Access to Cholangiocarcinoma Treatment in Hong Kong
Singapore-based precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto...